Management of EGFR-inhibitor associated rash: A retrospective study in 49 patients

European Journal of Medical Research

Volumn 17, Issue 1, 2012, Pages

  Gerber, Peter Arne ^a   Meller, Stephan ^a   Eames, Tatiana ^b   Buhren, Bettina Alexandra ^a   Schrumpf, Holger ^a   Hetzer, Sonja ^a   Ehmann, Laura Maximiliane ^b   Budach, Wilfried ^a   Bölke, Edwin ^a   Matuschek, Christiane ^a   Wollenberg, Andreas ^b   Homey, Bernhard ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

cetuximab; EGFR; erlotinib; gefitinib; panitumumab; papulopustular exanthema; rash

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ISOTRETINOIN; MOMETASONE FUROATE; NADIFLOXACIN; PREDNICARBATE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PREGNANE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINOLIZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ARTICLE; DISEASE SEVERITY; DRUG INDUCED DISEASE; EVENING DOSAGE; HUMAN; QUALITY OF LIFE; RASH; RETROSPECTIVE STUDY; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; PATHOLOGY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; EXANTHEMA; FLUOROQUINOLONES; HUMANS; ISOTRETINOIN; PREGNADIENEDIOLS; PROTEIN KINASE INHIBITORS; QUINOLIZINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84865786854     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-17-4     Document Type: Article

References (39)

1. EGFR antagonists in cancer treatment. Ciardiello F, Tortora G, N Engl J Med 2008 358 1160 1174 10.1056/NEJMra0707704 18337605
2. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, N Engl J Med 2011 364 2507 2516 10.1056/NEJMoa1103782 21639808
3. [Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects]. Gerber PA, Buhren BA, Kurle S, Homey B, Hautarzt 2010 61 654 661 10.1007/s00105-010-1943-6 20628713
4. Rosacea: the cytokine and chemokine network. Gerber PA, Buhren BA, Steinhoff M, Homey B, J Investig Dermatol Symp Proc 2011 15 40 47 10.1038/jidsymp.2011.9 22076326
5. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. Gutzmer R, Becker JC, Enk A, Garbe C, Hauschild A, Leverkus M, Reimer G, Treudler R, Tsianakas A, Ulrich C, Wollenberg A, Homey B, J Dtsch Dermatol Ges 2011 9 195 203 21059173
6. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, Trarbach T, Wollenberg A, Ann Oncol 2011 22 524 535 10.1093/annonc/mdq387 20709812
7. Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy. Eames T, Kroth J, Flaig MJ, Ruzicka T, Wollenberg A, Acta Derm Venereol 2010 90 202 203 10.2340/00015555-0792 20169314
8. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P, J Clin Oncol 2004 22 3238 3247 10.1200/JCO.2004.11.057 15310767
9. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ, Clin Cancer Res 2007 13 3913 3921 10.1158/1078-0432.CCR-06-2610 17606725
10. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, Lacouture ME, J Natl Cancer Inst 2010 102 47 53 10.1093/jnci/djp439 20007525
11. Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Forton F, Seys B, Br J Dermatol 1993 128 650 659 10.1111/j.1365-2133.1993.tb00261.x 8338749
12. Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. Gerber PA, Buhren BA, Cevikbas F, Bolke E, Steinhoff M, Homey B, J Am Acad Dermatol 2010 63 163 165 10.1016/j.jaad.2009.09. 023 20542181
13. More on aprepitant for erlotinib-induced pruritus. Gerber PA, Buhren BA, Homey B, N Engl J Med 2011 364 486 487 21288112
14. Images in clinical medicine. Erlotinib-induced hair alterations. Gerber PA, Homey B, N Engl J Med 2008 358 1175 10.1056/NEJMicm073144 18337606
15. Practical management of patients with non-small-cell lung cancer treated with gefitinib. Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Ben-Porat L, Sachs DL, Heelan RT, Miller VA, J Clin Oncol 2005 23 165 174 15557594
16. Cutaneous side effects of EGFR inhibitors-appearance and management. Wollenberg A, Kroth J, Hauschild A, Dirschka T, Dtsch Med Wochenschr 2010 135 149 154 10.1055/s-0029-1244831 20101558
17. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. Bernier J, Russi EG, Homey B, Merlano MC, Mesia R, Peyrade F, Budach W, Ann Oncol 2011 22 2191 2200 10.1093/annonc/mdr139 21606209
18. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Bolke E, Gerber PA, Lammering G, Peiper M, Muller-Homey A, Pape H, Giro C, Matuschek C, Bruch-Gerharz D, Hoffmann TK, Gripp S, Homey B, Budach W, Strahlenther Onkol 2008 184 105 110 10.1007/s00066-008-1829-z 18259703
19. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. Budach W, Bolke E, Homey B, N Engl J Med 2007 357 514 515 10.1056/NEJMc071075 17671265
20. Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors. Sartor CI, Nat Clin Pract Oncol 2004 1 80 87 16264825
21. Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects. Gerber PA, Enderlein E, Homey B, Muller A, Boelke E, Budach W, J Clin Oncol 2007 25 4697 4698 author reply 4698-4699 10.1200/JCO.2007.12.8330 17925571
22. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C, Segaert S, Ang KK, Ann Oncol 2008 19 142 149 17785763
23. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J, Br J Dermatol 2005 153 849 851 10.1111/j.1365-2133.2005.06835.x 16181478
24. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab-A report of 29 patients. Katzer K, Tietze J, Klein E, Heinemann V, Ruzicka T, Wollenberg A, Eur J Dermatol 2010 20 82 84 19797039
25. Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid. Wollenberg A, Moosmann N, Kroth J, Heinemann V, Klein E, Hautarzt 2007 58 615 618 10.1007/s00105-006- 1256-y 17146641
26. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Wollenberg A, Moosmann N, Klein E, Katzer K, Exp Dermatol 2008 17 790 792 10.1111/j.1600-0625.2008.00715.x 18503553
27. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. Tokumaru S, Sayama K, Shirakata Y, Komatsuzawa H, Ouhara K, Hanakawa Y, Yahata Y, Dai X, Tohyama M, Nagai H, Yang L, Higashiyama S, Yoshimura A, Sugai M, Hashimoto K, J Immunol 2005 175 4662 4668 16177113
28. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Prakash A, Benfield P, Drugs 1998 55 145 163 10.2165/00003495-199855010-00009 9463794
29. Clinical practice. Rosacea. Powell FC, N Engl J Med 2005 352 793 803 10.1056/NEJMcp042829 15728812
30. Glucocorticoid therapy-induced skin atrophy. Schoepe S, Schacke H, May E, Asadullah K, Exp Dermatol 2006 15 406 420 10.1111/j.0906-6705.2006.00435.x 16689857
31. Evaluation of the tissue toxicity of antiseptics by the hen's egg test on the chorioallantoic membrane (HETCAM). Marquardt C, Matuschek E, Bolke E, Gerber PA, Peiper M, Buhren BA, van Griensven M, Budach W, Hassan M, Kukova G, Mota R, Hofer D, Orth K, Fleischmann W, Eur J Med Res 2010 15 204 209 10.1186/2047-783X-15-5-204 20562059
32. Complicated skin, skin structure and soft tissue infections-are we threatened by multi-resistant pathogens? Kujath P, Kujath C, Eur J Med Res 2010 15 544 553 21163729
33. The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects. Gerber PA, Enderlein E, Homey B, J Clin Oncol 2008 26 2790 2792 10.1200/JCO.2007.16.0077 18509193
34. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC, J Clin Oncol 2007 25 5390 5396 10.1200/JCO.2007.12.6987 18048820
35. Multiresistant bacteria and current therapy-the economical side of the story. Wilke MH, Eur J Med Res 2010 15 571 576 10.1186/2047-783X-15-12-571 21163732
36. Epidermal growth factor receptor is a common mediator of quinone-induced signaling leading to phosphorylation of connexin-43: role of glutathione and tyrosine phosphatases. Abdelmohsen K, Gerber PA, von Montfort C, Sies H, Klotz LO, J Biol Chem 2003 278 38360 38367 10.1074/jbc.M306785200 12874275
37. Doxorubicin induces EGF receptor-dependent downregulation of gap junctional intercellular communication in rat liver epithelial cells. Abdelmohsen K, von Montfort C, Stuhlmann D, Gerber PA, Decking UK, Sies H, Klotz LO, Biol Chem 2005 386 217 223 10.1515/BC.2005.027 15843167
38. 2-Methyl-1,4-naphthoquinone, vitamin K(3), decreases gap-junctional intercellular communication via activation of the epidermal growth factor receptor/extracellular signal-regulated kinase cascade. Klotz LO, Patak P, Ale-Agha N, Buchczyk DP, Abdelmohsen K, Gerber PA, von Montfort C, Sies H, Cancer Res 2002 62 4922 4928 12208742
39. Skin toxicities associated with epidermal growth factor receptor inhibitors. Li T, Perez-Soler R, Target Oncol 2009 4 107 119 10.1007/s11523-009-0114-0 19452131